Drug intelligence / Profile preview

LY4057996

Development stage: Phase 1
Lead developer: Eli Lilly
Administration: Subcutaneous, Intravenous

Overview

LY4057996 is an investigational therapeutic agent being developed by Eli Lilly for the treatment of type 1 and type 2 diabetes mellitus. The drug is currently undergoing Phase 1 clinical studies to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy participants and those with diabetes. LY4057996 is administered via subcutaneous or intravenous injection. As of now, the specific mechanism of action, molecular target, and chemical modality of LY4057996 have not been publicly disclosed by the developer[1][2][5].

Other names: LY-4057996LY4057996LY 4057996

Beyond the preview

Go deeper on LY4057996.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4057996.

Explore the full profile